Skip to main content

Articles By Jack Cush, MD

2021,year

2021 Rheumatology Year in Review

By Jack Cush, MD
08 January 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
pill pillbox adherence

Comorbidities Drive Risk of Severe Outcomes with COVID-19

By Jack Cush, MD
06 January 2022

The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

By Jack Cush, MD
05 January 2022

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article
COVID,teen,young,man,mask

Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children

By Jack Cush, MD
05 January 2022

Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. A review of proposed management guidelines is compiled in this report, suggesting a unified approach to therapeutic management of MIS-C.

Read Article
PSS.scleroderma.arthritis.contractures

Autoantibody Associations in Systemic Sclerosis

By Jack Cush, MD
04 January 2022

Analysis of two large cohorts of systemic sclerosis (SSc) patients shows a signfiicant minority of patients to have autoantibodies typical of rheumatoid erosive arthrits, but their presence in SSc patients was associated with unique manifestations of SSc. 

Read Article
psor.elb_.jpg

Spesolimab, an IL-36 Blocker, in Pustular Psoriasis

By Jack Cush, MD
03 January 2022

The NEJM has published the results of a phase 2 randomized trial showing that the use of an interleukin-36 receptor inhibitor, spesolimab, resulted in rapid improvement of generalized pustular psoriasis (at 1 week), but that adverse events and infections were of concern with 12 weeks of followup.

Read Article
covid vaccine needle vaccination

Safety of COVID-19 Vaccines in Rheumatic Patients

By Jack Cush, MD
03 January 2022

Since the introduction of COVID-19 vaccines in January 2021, rheumatologists have fully advocated the protective benefits of their use - yet many have rarely noted flares and reactive side effects worrisome to patients.  Now a multinational study shows that the use of COVID vaccination in rheumatic and musculoskeletal disease is safe, well-tolerated with very rare serious adverse events.

Read Article
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

By Jack Cush, MD
31 December 2021

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen journal articles, news reports and questions + cases.

Read Article
FDA.Safety.jpg

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

By Jack Cush, MD
30 December 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying a JAK inhibitor. These recommendations apply to tofacitinib, baricitinib and upadacitinib.

Read Article
COVID vaccine vials

Best of 2021: Comparison of Three Coronavirus Vaccines

By Jack Cush, MD
30 December 2021

On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available.  We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth. 

Read Article
×